The saw that with 525mg and 700mg, leronlimab can do better in the MDR2 group, maybe significantly better than 81%. Leronlimab 350mg clearly jumped over the bar, by almost double previous approvals. So it would have gotten approval without the other data available I feel. But the FDA seems to want to squeeze out the very best results, even though what they have at 350mg is exceptional. Unfortunately Cydy is pre revenue biotech, that model or concept is killing us here.